UroGen Pharma (URGN) announced that Chris Degnan has been appointed CFO. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. Degnan joins UroGen with extensive experience as a publicly traded biotech CFO, most recently at Galera Therapeutics (GRTX).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
Questions or Comments about the article? Write to editor@tipranks.com